INSIGHTS

Articles & Insights.

Thought leadership on the legal, regulatory, and business issues shaping the healthcare industry.

REAL ISSUES.

PRACTICAL INSIGHTS.

AHEAD OF THE CURVE.

California Expands Healthcare Transaction Oversight: MSOs and Private Equity Investors Face New Requirements

California Expands Healthcare Transaction Oversight: MSOs and Private Equity Investors Face New Requirements

Healthcare investors have become accustomed to evaluating corporate practice of medicine restrictions when acquiring medical practices or entering new markets.

California is adding another important consideration: regulatory scrutiny of healthcare transactions before closing.

On October 2, 2026, California’s Office of Administrative Law approved amendments to the Office of Health Care Affordability’s healthcare transaction review regulations. The amendments become effective November 2, 2026, expanding the state’s oversight of certain transactions involving private equity groups, hedge funds, and Management Services Organizations.

The changes implement portions of AB 1415, which became effective January 1, 2026. 

Healthcare Transactions Are No Longer Just Private Business Decisions

Traditionally, healthcare acquisitions have involved negotiations between buyers and sellers concerning purchase price, liabilities, employment agreements, regulatory approvals, and post-closing operations.

California’s framework adds another layer.

Covered transactions may require notification to OHCA at least 90 days before closing. Depending on the circumstances, the transaction cannot close until the applicable regulatory review process has been completed.

Importantly, these requirements are not limited to acquisitions of hospitals.

Professional practices, management companies, and investor-backed healthcare platforms may also fall within the expanded framework.

Why MSOs Are Particularly Important

Many healthcare investors use MSO structures to participate economically in healthcare businesses while maintaining separate professional entities responsible for clinical services.

The new regulations broaden the circumstances under which MSOs and their investors may become subject to transaction review.

Certain investments involving the acquisition of at least 10% of a healthcare entity’s or MSO’s assets, equity, debt, or liabilities can trigger notification requirements. Transactions involving smaller interests may also be covered when governance or control rights accompany the investment.

MSOs may face additional filing obligations depending on their revenue relationships, affiliations, and involvement in changes of control. 

This is significant because healthcare investors frequently structure transactions around management rights rather than direct professional ownership.

Those management rights can now affect whether a transaction requires regulatory notification.

Transparency Extends Beyond the Acquired Practice

Another significant development concerns disclosure.

The framework requires substantial information regarding organizational structure and ownership.

Depending on the transaction, disclosures may extend beyond the immediate buyer and seller to affiliated entities, ownership interests, and other healthcare investments within the broader organization.

For private equity sponsors managing multiple healthcare investments, this increases the importance of maintaining accurate organizational records.

It also creates confidentiality considerations because filings are generally presumed to be public unless appropriate confidential treatment is requested and granted.

Transaction Timelines Must Change

These requirements should be considered before signing a purchase agreement.

A buyer expecting to close within 30 days may discover that the transaction requires a substantially longer regulatory timeline.

Letters of intent and purchase agreements should address notification responsibilities, cooperation obligations, filing expenses, regulatory contingencies, termination rights, and outside closing dates.

The Larger Trend

California’s new framework demonstrates how healthcare investment regulation continues to expand beyond traditional physician-ownership requirements.

Investors increasingly must evaluate not only whether they can legally acquire or manage a healthcare business, but also whether regulators must review the transaction itself.

Apex Health Law advises healthcare investors, MSOs, physicians, and healthcare businesses regarding transactions, professional ownership restrictions, management structures, and multi-state expansion.

This article is provided for general informational purposes only and does not constitute legal advice.

Regulatory reference: California Office of Health Care Affordability regulations⁠

Share:

More Posts

Send A Message